Plans for exploring the effects of MABp1 as a combination therapy in oncology are ongoing. MABp1’s strong potential as a combination therapy was highlighted in a commentary piece which accompanied the most recent Lancet Publication. The commentary noted that combining agents that target inflammation, such as MABp1, with first and second lines of therapy could improve outcomes and survival in advanced cancer patients. Furthermore, given the excellent safety profile of MABp1, combining it with chemotherapy and/or biological agents are promising options given the recruitment of anti-tumor inflammatory cells seen in patients refractory to these drugs. XBiotech is currently exploring options to assess the potential of MABp1 in combination with other treatments including chemotherapy, EGFR inhibitors and immune check point inhibitors.
In September 2017, the Company announced an agreement with Cedars-Sinai to conduct an investigator-initiated, Phase I single arm study evaluating the maximum tolerated dose of OnivydeⓇ (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status.